biostudies-literatureUnknown8(2)Begre L<h4>Background & aims</h4>HBsAg loss improves clinical outcomes in persons with HIV and HBV coinfection. We aimed to evaluate if hepatitis B core-related antigen and circulating HBV RNA levels were associated with HBsAg loss in Euro-B, a multi-cohort collaboration including data from the Swiss HIV Cohort Study, EuroSIDA, and the French HIV/HBV cohort.<h4>Methods</h4>We included persons with HIV, a positive HBsAg, and ≥6 months of follow-up on tenofovir-containing antiretroviral therapy. We evaluated quantitative HBsAg, HBV DNA, hepatitis B core-related antigen, and HBV RNA levels over time and assessed HBsAg loss (<i>i.e.</i> quantitative HBsAg <0.05 IU/ml) during tenofovir therapy.<h4>Results</h4>Among 599 participants median age was 41 years (IQR 35-47), 18.4% were female and 47.3% HBeAgJHEP reports : innovation in hepatology101671https://www.ebi.ac.uk/biostudies/studies/S-EPMC12803887biostudies-literatureCirculating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe.PMC12803887Anagnostopoulos AParedes RKnappik MBoffito MMackintosh CHuber MLarsen JFJablonowska ENesterova ONicca DTimiryasova ALundgren JGardizi MDegen OHosli IShahi SHetman LOstergaard LKumar LRZoulim FTrofimova TGracia MGReikvam DHMachala LLacombe KChivite IBernasconi EBeguelin CElbirt DRoper FDevitt EPuig JBogner JFurrer HGirard PMMarzolini CStockle MMansinho KSuter-Riniker FKamerys JAmbrosioni JCozzi-Lepri AF SRMitsura VMLabhardt NDAksak-Was BCarlander CKowalska JDSedlacek DFoncillas ADe Scheerder MFux CABatutu RPlissonnier MLKundro MKlimkait TSwiss HIV Cohort Study, EuroSIDA and French HIV/HBV and Biliver cohortsJohansen ISMuller NWinston ABlanco JLStefan CBattegay MLevrero MSzetela BDelforge MTrkola ACalmy APeters LGonzalez-Cordon AYerly SBraun DBraun DLKuznetsova AAebi-Popp KWattad LMBoyd ARougier HInglot MGuaraldi GDuvivier CDe A Arroniz ESTrajanovska JBenfield TZilmer KWeisser MMartinez EKeiser OLascoux-Combe CPaissios NMansson FParczewski MRasmussen LDRockstroh JBerrocal LViard JPPantaleo GBrannstrom JAdamis GWandeler GTarr PEBeniowski MMora LInciarte ALosso MAho IBurns FMiranda CNemeth JRozplochowski BValk MVCichon PWiese LMaltez FDollenmaier GRanin JElzi LHoffmann CLaguno MDe Wit SAbela IAKnysz BLehmann CDomingo PKryshchuk ADelaugerre Cde Lazzaari EEdwards SMembers of the French HIV/HBV and Biliver cohortsSchiavo FTopalovic JMiro JMPepa BSchmid PJackson-Perry DNeesgaard BHoffmann MAbutidze AKuzovatova EGusev DSegeral OElsing TWSzlavik JEgger MFellay JNozza SPerreau MPradier CMozer-Lisewska ICastagna AVdoushkina EKirk OTorres BPonz ANielsen LNScholtes CSantos JRTestoni BHarxhi ASarcletti MMembers of the EuroSIDA Study GroupFontas EOprea CSalazar-Vizcaya LPElinav HCallau PKouyos RDUzdaviniene VZagalo ATau LOrkin CClarke AMartinez de Tejada BGunthard HFMularska EMetzner KJHachfeld ABegre LFehr JSBorodulina EWojcik KKarpov IKahlert CRFrankenhuijsen MJilich DTomazic JMiailhes PBegovac JStaub TPaduto DMatulionyte RRauch ABondarenko OASonnerborg AHeil MPaioni PHirsch HHFalconer KRockstroh JKGerstoft JHasse BMallolas JGozlan JNotter JMarchetti GLeuzinger KMartinez-Rebollar MSambatakou HFischer AHCavassini MKusejko KRaben DPenzing KChas JBannister WJaschinski NBucher HCClumeck NGottfredsson MAlcami JCiuffi ABoesecke CLebech AMRidolfo AMar GMMussini CRadoi RBakowska EKovari HHans-Ulrich Haerry DfalseCirculating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe.<h4>Background & aims</h4>HBsAg loss improves clinical outcomes in persons with HIV and HBV coinfection. We aimed to evaluate if hepatitis B core-related antigen and circulating HBV RNA levels were associated with HBsAg loss in Euro-B, a multi-cohort collaboration including data from the Swiss HIV Cohort Study, EuroSIDA, and the French HIV/HBV cohort.<h4>Methods</h4>We included persons with HIV, a positive HBsAg, and ≥6 months of follow-up on tenofovir-containing antiretroviral therapy. We evaluated quantitative HBsAg, HBV DNA, hepatitis B core-related antigen, and HBV RNA levels over time and assessed HBsAg loss (<i>i.e.</i> quantitative HBsAg <0.05 IU/ml) during tenofovir therapy.<h4>Results</h4>Among 599 participants median age was 41 years (IQR 35-47), 18.4% were female and 47.3% HBeAg2026-01-01T00:00:00Z2026 Feb2026-06-13T04:49:43.147Z2026-06-13T03:09:17.749ZS-EPMC128038874155141210.1016/j.jhepr.2025.101671